Jiliang Gao

Title: Jiliang Gao: Innovator in Hematopoietic Stem Cell Research

Introduction

Jiliang Gao is a prominent inventor based in Potomac, MD (US). He has made significant contributions to the field of hematopoietic stem cell research. His innovative approaches aim to enhance the engraftment of these vital cells in recipient subjects.

Latest Patents

Gao holds a patent titled "Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells." This patent outlines methods for improving the engraftment of hematopoietic stem cells (HSC) by reducing the expression or activity of CXC chemokine receptor 4 (CXCR4). The techniques described can be utilized in gene therapy protocols and HSC transplantation, potentially allowing these procedures to occur without the need for radiation or chemotherapy conditioning, which is typically required in non-myeloablative HSC transplants. In certain instances, gene editing methods are employed to delete one copy of the CXCR4 gene prior to HSC or bone marrow transplantation, thereby enhancing the efficiency and durability of donor cell repopulation.

Career Highlights

Gao is affiliated with the United States of America, as represented by the Secretary, Department of Health and Human Services. His work focuses on advancing the understanding and application of hematopoietic stem cell therapies.

Collaborations

Gao has collaborated with notable colleagues, including David H McDermott and Harry L Malech. Their combined expertise contributes to the advancement of research in this critical area of medicine.

Conclusion

Jiliang Gao's innovative work in hematopoietic stem cell research and his patent on enhancing engraftment methods highlight his significant contributions to the field. His efforts pave the way for improved therapeutic strategies in stem cell transplantation.